Journal
JOURNAL OF HEART AND LUNG TRANSPLANTATION
Volume 27, Issue 4, Pages 462-465Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.healun.2008.01.005
Keywords
-
Ask authors/readers for more resources
Pulmonary lymphangioleiomyomatosis (PLAM) is an indication for lung transplantation (LTx). Angiomyolipomas occur in approximately 50% to 60% of patients with PLAM. We describe a patient presenting with hemoptysis post-LTx for PLAM. Computed tomography (CT) scan demonstrated no pulmonary abnormality, but identified a retroperitoneal mass confirmed as angiomyotipoma by CT-guided core biopsy. Based on experimental work that rapamycin may inhibit angiomyotipoma cells, we commenced the patient on low-dose rapamycin. She had no adverse reactions and follow-up CT scan after 7 months demonstrated almost complete resolution of the tumor. This suggests a role for rapamycin in routine post-LTx immunosuppression for PLAM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available